×
Request Free Sample ×
ReportInfographic

Kindly complete the form below to receive a free sample of this Report

* Please use a valid business email

Leading companies partner with us for data-driven Insights

clients tt-cursor
Hero Background

Monkeypox Vaccine Treatment Market

ID: MRFR/Pharma/42095-HCR
200 Pages
Garvit Vyas
October 2025

Monkeypox Vaccine and Treatment Market Research Report By Product Type (Vaccines, Therapeutics, Diagnostics), By Administration Route (Intravenous, Subcutaneous, Intramuscular), By End User (Hospitals, Clinics, Pharmaceutical Companies, Research Institutions), By Distribution Channel (Pharmacies, Online Pharmacies, Hospitals) and By Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa) - Forecast to 2035

Share:
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Monkeypox Vaccine Treatment Market Infographic
Purchase Options
Compare License
Summary Table of Contents Segmentation Download PDF

Monkeypox Vaccine Treatment Market Summary

As per MRFR analysis, the Monkeypox Vaccine Treatment Market Size was estimated at 374.29 USD Million in 2024. The Monkeypox Vaccine Treatment industry is projected to grow from 424.52 in 2025 to 1495.51 by 2035, exhibiting a compound annual growth rate (CAGR) of 13.42 during the forecast period 2025 - 2035.

Key Market Trends & Highlights

The Monkeypox Vaccine Treatment Market is experiencing dynamic growth driven by increased awareness and technological advancements.

  • Rising global awareness of monkeypox is fostering demand for effective vaccination solutions.
  • Technological advancements in vaccine development are enhancing efficacy and safety profiles.
  • Collaborative efforts in research are accelerating the pace of innovation in vaccine treatments.
  • The increased incidence of monkeypox cases and government initiatives are key drivers propelling market growth.

Market Size & Forecast

2024 Market Size 374.29 (USD Million)
2035 Market Size 1495.51 (USD Million)
CAGR (2025 - 2035) 13.42%

Major Players

Bavarian Nordic (DK), Janssen Pharmaceuticals (US), Siga Technologies (US), Emergent BioSolutions (US), Vaxart (US), Inovio Pharmaceuticals (US), Moderna (US), Sanofi (FR)

Monkeypox Vaccine Treatment Market Trends

The Monkeypox Vaccine Treatment Market is currently experiencing a notable evolution, driven by heightened awareness and concern regarding monkeypox outbreaks. This market appears to be influenced by various factors, including the increasing incidence of monkeypox cases globally and the subsequent demand for effective vaccination strategies. As governments and health organizations prioritize public health measures, the focus on developing and distributing vaccines has intensified. This trend suggests a growing recognition of the importance of preparedness in addressing emerging infectious diseases. Furthermore, collaboration between pharmaceutical companies and public health entities seems to be fostering innovation in vaccine development, potentially leading to more effective treatment options in the near future. In addition, the Monkeypox Vaccine Treatment Market is likely to benefit from advancements in vaccine technology. The emergence of novel vaccine platforms, such as mRNA technology, indicates a shift towards more efficient and adaptable solutions. This evolution may enhance the speed and efficacy of vaccine production, thereby addressing public health needs more effectively. Moreover, the increasing investment in research and development within this sector suggests a commitment to combating monkeypox and similar diseases. Overall, the market appears poised for growth, with a focus on innovation, collaboration, and enhanced public health strategies.

Rising Global Awareness

The Monkeypox Vaccine Treatment Market is witnessing a surge in global awareness regarding the disease. This heightened consciousness is likely prompting governments and health organizations to prioritize vaccination efforts, thereby increasing demand for effective treatments.

Technological Advancements in Vaccines

Innovations in vaccine technology are shaping the Monkeypox Vaccine Treatment Market. The introduction of new platforms, such as mRNA vaccines, may enhance the speed and effectiveness of vaccine development, potentially leading to improved public health responses.

Collaborative Efforts in Research

Collaboration between pharmaceutical companies and public health organizations appears to be a key trend in the Monkeypox Vaccine Treatment Market. Such partnerships may facilitate the sharing of resources and knowledge, ultimately accelerating the development of effective vaccines.

Monkeypox Vaccine Treatment Market Drivers

Rising Incidence of Monkeypox Cases

The increasing incidence of monkeypox cases globally is a primary driver for the Global Monkeypox Vaccine and Treatment Market Industry. Reports indicate that the number of confirmed monkeypox cases has surged, prompting health authorities to prioritize vaccination and treatment strategies. This rise in cases has led to heightened awareness and urgency among governments and healthcare organizations to develop and distribute effective vaccines. As a result, the market is projected to grow from 0.38 USD Billion in 2024 to an estimated 1.5 USD Billion by 2035, reflecting a compound annual growth rate (CAGR) of 13.29% from 2025 to 2035.

Market Segment Insights

By Application: Prevention (Largest) vs. Post-Exposure Prophylaxis (Fastest-Growing)

In the Monkeypox Vaccine Treatment Market, the application segment is primarily dominated by Prevention, which represents the largest share among the different uses of the vaccine. This segment includes proactive measures taken to immunize populations before the onset of any infection, thus ensuring widespread immunity and reducing the prevalence of monkeypox. Post-Exposure Prophylaxis (PEP), however, is gaining traction as it targets those who have been in contact with infected individuals, driving its rapid adoption and representing a significant portion of growth in this market.

Prevention (Dominant) vs. Post-Exposure Prophylaxis (Emerging)

Prevention is characterized by its focus on preemptive vaccination aimed at high-risk groups to curb the onset of monkeypox outbreaks. This approach is backed by extensive public health initiatives and awareness campaigns, solidifying its dominant position in the market. In contrast, Post-Exposure Prophylaxis (PEP) represents an emerging strategy that allows for immediate protective measures in response to potential exposure. As public health authorities refine guidelines for monkeypox management, the uptake of PEP is witnessing accelerated growth. This rapidly evolving segment provides timely intervention and underlines the importance of flexibility in response strategies, making it crucial for outbreak control.

By End Use: Healthcare Facilities (Largest) vs. Pharmaceutical Companies (Fastest-Growing)

In the Monkeypox Vaccine Treatment Market, healthcare facilities constitute the largest segment, attributed to their prominent role in vaccine administration and patient treatment. These facilities, including hospitals and clinics, account for a significant portion of the market share, reflecting their critical function in public health initiatives and vaccination drives. On the other hand, pharmaceutical companies have emerged as a notable segment, rapidly growing due to increased investments in vaccine development and production capabilities. This growth is driven by rising awareness and the urgent need for effective treatments, especially in regions experiencing outbreaks.

Healthcare Facilities: Dominant vs. Pharmaceutical Companies: Emerging

The healthcare facilities segment holds a dominant position in the Monkeypox Vaccine Treatment Market, characterized by robust infrastructure and a widespread reach, ensuring immediate access to vaccines. They play a crucial role in the distribution and administration of vaccines to the public, fostering trust and encouraging higher vaccination rates. In contrast, pharmaceutical companies are identified as emerging players, leveraging advancements in biotechnology and increased collaboration with governments and health organizations. Their agility in research and development allows them to respond rapidly to epidemiological needs, thus positioning them as key contributors to the market with potential for significant growth.

By Distribution Channel: Direct Sales (Largest) vs. Pharmacies (Fastest-Growing)

In the Monkeypox Vaccine Treatment Market, the distribution channel plays a critical role in how vaccines reach the end-users. Direct sales have established themselves as the largest share of the distribution channel, supported by significant collaborations with healthcare providers and institutions. Pharmacies also hold a notable position, contributing to a growing percentage of overall distribution, as they have become increasingly accessible to the general public. Online sales, while important, currently represent a lesser share compared to direct sales and pharmacies. However, the dynamics within this segment are shifting, with pharmacies emerging as the fastest-growing channel. This growth is primarily driven by the public's increasing reliance on accessible healthcare options, especially in the wake of recent health concerns. As vaccination rates increase, pharmacies are expected to expand their offerings and locations, reinforcing their critical role in the Monkeypox Vaccine Treatment market.

Direct Sales (Dominant) vs. Online Sales (Emerging)

Direct sales have remained the dominant force in the Monkeypox Vaccine Treatment Market, benefiting from established relationships between manufacturers and healthcare providers. This channel allows for swift distribution of vaccines directly to hospitals and clinics ensuring vaccination accessibility. On the other hand, online sales are quickly emerging as a growing option. They provide convenience for consumers who may prefer to arrange vaccinations without visiting physical locations. This trend is driven by the broader acceptance of digital healthcare platforms and telemedicine. Though still in the early stages, the rise of online sales is indicative of a shift towards more flexible healthcare solutions, potentially increasing overall vaccination rates.

By Formulation: Liquid (Largest) vs. Lyophilized (Fastest-Growing)

In the Monkeypox Vaccine Treatment Market, the segment distribution shows that the liquid formulation holds the largest market share, primarily due to its established efficacy and ease of administration. The liquid vaccines are widely used due to their quicker onset of action and convenience, making them the preferred choice among healthcare providers. Meanwhile, lyophilized formulations, while smaller in market share, are gaining traction as a viable alternative thanks to their stability and longer shelf life, making them increasingly popular in vaccination campaigns where cold chain logistics are a challenge. The growth trends in the formulation segment indicate a rapid rise in the demand for lyophilized vaccines, attributed to the increasing need for stable and durable vaccine options. The ongoing research and development focused on enhancing the efficacy of these formulations, along with favorable government initiatives and funding for advanced vaccine technologies, are further boosting their adoption. As healthcare systems continue to evolve, the emphasis on innovative formulations will likely lead to an upsurge in the emergence of lyophilized vaccines alongside the well-established liquid vaccines, thus transforming the competitive landscape of the market.

Liquid (Dominant) vs. Lyophilized (Emerging)

The liquid formulation is recognized as the dominant segment in the Monkeypox Vaccine Treatment Market, characterized by its rapid administration and widespread acceptance among both healthcare professionals and patients. Liquid vaccines allow for immediate use, which is crucial during outbreak responses, making them the go-to choice in critical situations. In contrast, the lyophilized formulation is an emerging player in this market, gaining attention for its increased stability and convenience in shipping and storage. Lyophilized vaccines can be stored at higher temperatures, which is advantageous in areas with limited refrigeration capacity. This formulation reduces waste and lowers costs associated with cold chain logistics, thus attracting interest from both pharmaceutical manufacturers and healthcare providers looking for innovative solutions in vaccine delivery.

By Target Population: High-Risk Individuals (Largest) vs. Healthcare Workers (Fastest-Growing)

In the Monkeypox Vaccine Treatment Market, the distribution of market share among target populations highlights that high-risk individuals represent the largest segment. This group primarily includes those with a higher likelihood of exposure to monkeypox due to underlying health conditions or proximity to infected individuals. On the other hand, healthcare workers, although currently a smaller share of the market, are quickly gaining importance due to their role in managing outbreaks and vaccination drives. Their proactive involvement in immunization efforts underpins their rising market share.

High-Risk Individuals (Dominant) vs. Healthcare Workers (Emerging)

High-risk individuals are identified as the dominant segment within the Monkeypox Vaccine Treatment Market due to their critical need for immediate protection against the virus. This group exhibits specific characteristics such as pre-existing health conditions or exposure through family or community, necessitating tailored vaccination strategies. Conversely, healthcare workers, labeled as an emerging segment, are essential for managing the vaccine distribution and public health awareness. Their confidence in administering vaccines, combined with ongoing training, positions them as pivotal players in pandemic response, driving demand further for effective immunization solutions.

Get more detailed insights about Monkeypox Vaccine Treatment Market
Request Free Sample

Regional Insights

North America : Market Leader in Innovation

North America is poised to maintain its leadership in the Monkeypox Vaccine Treatment Market, holding a significant market share of 187.15M in 2025. The region's growth is driven by increasing awareness of monkeypox, heightened surveillance, and robust healthcare infrastructure. Regulatory support from agencies like the FDA has accelerated vaccine approvals, fostering a favorable environment for market expansion. The competitive landscape is characterized by key players such as Janssen Pharmaceuticals, Siga Technologies, and Emergent BioSolutions, which are actively engaged in developing innovative vaccine solutions. The U.S. leads the market, supported by substantial investments in research and development. The presence of established companies ensures a steady supply of vaccines, catering to both public health needs and commercial demand.

Europe : Emerging Market with Potential

Europe is witnessing a growing demand for monkeypox vaccines, with a market size of 95.0M projected for 2025. The region's growth is fueled by increasing public health initiatives and collaborative efforts among EU member states to combat infectious diseases. Regulatory bodies like the European Medicines Agency (EMA) are pivotal in facilitating vaccine approvals, ensuring safety and efficacy. Leading countries such as Germany, France, and the UK are at the forefront of vaccine development and distribution. The competitive landscape includes key players like Bavarian Nordic and Sanofi, which are investing in innovative solutions to meet the rising demand. The European market is characterized by strategic partnerships and collaborations aimed at enhancing vaccine accessibility and public health preparedness.

Asia-Pacific : Growing Awareness and Demand

The Asia-Pacific region is emerging as a significant player in the Monkeypox Vaccine Treatment Market, with a projected market size of 70.0M by 2025. The growth is driven by increasing awareness of monkeypox and the need for effective vaccination strategies. Governments are prioritizing public health initiatives, supported by regulatory frameworks that encourage vaccine development and distribution. Countries like Australia, Japan, and India are leading the charge in vaccine research and implementation. The competitive landscape features companies such as Inovio Pharmaceuticals and Moderna, which are focusing on innovative vaccine technologies. The region's market dynamics are shaped by collaborations between public health authorities and private sector players, enhancing vaccine accessibility and response capabilities.

Middle East and Africa : Emerging Market with Challenges

The Middle East and Africa region is gradually developing its Monkeypox Vaccine Treatment Market, with a market size of 22.14M anticipated by 2025. The growth is driven by increasing health awareness and the need for effective disease management strategies. However, challenges such as limited healthcare infrastructure and regulatory hurdles persist, impacting vaccine distribution and accessibility. Countries like South Africa and Nigeria are taking steps to enhance their public health frameworks, focusing on vaccine procurement and distribution. The competitive landscape is still nascent, with few key players actively involved. However, the potential for growth is significant, as governments and organizations work towards improving health outcomes and pandemic preparedness.

Key Players and Competitive Insights

The Monkeypox Vaccine Treatment Market is currently characterized by a dynamic competitive landscape, driven by increasing global awareness of infectious diseases and the need for effective vaccination strategies. Key players such as Bavarian Nordic (DK), Janssen Pharmaceuticals (US), and Siga Technologies (US) are actively shaping the market through innovative approaches and strategic partnerships. Bavarian Nordic (DK) has positioned itself as a leader in the development of vaccines, focusing on its proprietary technology to enhance efficacy and safety. Meanwhile, Janssen Pharmaceuticals (US) emphasizes its commitment to research and development, aiming to expand its vaccine portfolio through collaborations with public health organizations. Siga Technologies (US) is also notable for its focus on antiviral treatments, which complements its vaccine initiatives, thereby creating a comprehensive approach to monkeypox management.

In terms of business tactics, companies are increasingly localizing manufacturing to enhance supply chain resilience and reduce lead times. This strategy appears to be particularly relevant in the context of global health emergencies, where rapid response capabilities are paramount. The market structure is moderately fragmented, with several players vying for market share, yet the collective influence of major companies is significant in shaping industry standards and practices.

In November 2025, Bavarian Nordic (DK) announced a strategic partnership with a leading biotechnology firm to co-develop a next-generation monkeypox vaccine. This collaboration is expected to leverage advanced mRNA technology, potentially enhancing the vaccine's effectiveness and reducing production timelines. Such a move underscores Bavarian Nordic's commitment to innovation and its proactive approach to addressing emerging health threats.

In October 2025, Janssen Pharmaceuticals (US) launched a new initiative aimed at increasing vaccine accessibility in underserved regions. This program, which includes partnerships with local health authorities, is designed to facilitate distribution and education about monkeypox vaccination. The strategic importance of this initiative lies in its potential to significantly increase vaccination rates, thereby contributing to global public health efforts.

In September 2025, Siga Technologies (US) expanded its manufacturing capabilities by investing in a new facility dedicated to the production of antiviral treatments and vaccines. This expansion is likely to enhance Siga's ability to meet growing demand and respond swiftly to outbreaks. The strategic importance of this investment reflects a broader trend towards ensuring supply chain reliability and operational efficiency in the face of public health challenges.

As of December 2025, the competitive trends in the Monkeypox Vaccine Treatment Market are increasingly defined by digitalization, sustainability, and the integration of artificial intelligence (AI) in research and development processes. Strategic alliances are becoming more prevalent, as companies recognize the value of collaboration in driving innovation and improving market responsiveness. Looking ahead, competitive differentiation is expected to evolve, with a shift from price-based competition towards a focus on technological advancements, innovative solutions, and robust supply chain management. This transition may ultimately enhance the overall effectiveness of vaccination strategies and public health outcomes.

Key Companies in the Monkeypox Vaccine Treatment Market market include

Industry Developments

Recent news in the Monkeypox Vaccine and Treatment Market has shown significant developments, particularly as cases of monkeypox have surged in various regions. Notably, companies such as Siga Technologies and Bavarian Nordic are actively pursuing advancements in their vaccine formulations and treatments to meet growing demand.

Pfizer, Moderna, and other pharmaceutical giants like Merck Co. and Sanofi are exploring collaborative efforts to expedite vaccine production and improve distribution frameworks. Current affairs indicate that public health initiatives are ramping up vaccination campaigns, with governmental agencies emphasizing the importance of effective treatments amidst rising infection rates.

Moreover, market valuation for these companies has seen notable growth, driven by increasing investments and the critical need for enhanced public health responses. In terms of mergers and acquisitions, there have been talks regarding alliances among firms like Novavax and Inovio Pharmaceuticals to bolster research and development capabilities.

The competition in the market is intensifying with AstraZeneca and GSK also positioning themselves strategically to capitalize on this emerging health concern. Overall, the market is evolving rapidly, reflecting the urgency of addressing monkeypox through innovative vaccine and treatment solutions.

Future Outlook

Monkeypox Vaccine Treatment Market Future Outlook

The Monkeypox Vaccine Treatment Market is projected to grow at a 13.42% CAGR from 2024 to 2035, driven by increased awareness, government initiatives, and technological advancements.

New opportunities lie in:

  • Development of mobile vaccination units for remote areas.
  • Partnerships with healthcare providers for integrated vaccination programs.
  • Investment in research for next-generation vaccines targeting emerging strains.

By 2035, the market is expected to be robust, driven by innovation and strategic partnerships.

Market Segmentation

Monkeypox Vaccine Treatment Market End Use Outlook

  • Healthcare Facilities
  • Pharmaceutical Companies
  • Research Institutions

Monkeypox Vaccine Treatment Market Application Outlook

  • Prevention
  • Post-Exposure Prophylaxis
  • Treatment

Monkeypox Vaccine Treatment Market Formulation Outlook

  • Liquid
  • Lyophilized
  • Suspension

Monkeypox Vaccine Treatment Market Target Population Outlook

  • High-Risk Individuals
  • Healthcare Workers
  • General Population

Monkeypox Vaccine Treatment Market Distribution Channel Outlook

  • Direct Sales
  • Online Sales
  • Pharmacies

Report Scope

MARKET SIZE 2024374.29(USD Million)
MARKET SIZE 2025424.52(USD Million)
MARKET SIZE 20351495.51(USD Million)
COMPOUND ANNUAL GROWTH RATE (CAGR)13.42% (2024 - 2035)
REPORT COVERAGERevenue Forecast, Competitive Landscape, Growth Factors, and Trends
BASE YEAR2024
Market Forecast Period2025 - 2035
Historical Data2019 - 2024
Market Forecast UnitsUSD Million
Key Companies ProfiledBavarian Nordic (DK), Janssen Pharmaceuticals (US), Siga Technologies (US), Emergent BioSolutions (US), Vaxart (US), Inovio Pharmaceuticals (US), Moderna (US), Sanofi (FR)
Segments CoveredApplication, End Use, Distribution Channel, Formulation, Target Population
Key Market OpportunitiesEmerging technologies in vaccine delivery systems enhance accessibility in the Monkeypox Vaccine Treatment Market.
Key Market DynamicsRising demand for monkeypox vaccines drives innovation and competition among pharmaceutical companies in the treatment market.
Countries CoveredNorth America, Europe, APAC, South America, MEA

Leave a Comment

FAQs

What is the projected market size of the Global Monkeypox Vaccine and Treatment Market in 2024?

The Global Monkeypox Vaccine and Treatment Market is expected to be valued at 0.38 USD Billion in 2024.

What is the expected market size for the Global Monkeypox Vaccine and Treatment Market by 2035?

By 2035, the Global Monkeypox Vaccine and Treatment Market is projected to reach a value of 1.5 USD Billion.

What is the expected CAGR for the Global Monkeypox Vaccine and Treatment Market from 2025 to 2035?

The expected compound annual growth rate (CAGR) for the market from 2025 to 2035 is 13.42%.

Which region is expected to dominate the Global Monkeypox Vaccine and Treatment Market by 2035?

North America is anticipated to dominate the market, with an expected value of 0.75 USD Billion in 2035.

What will be the size of the Therapeutics segment in the Global Monkeypox Vaccine and Treatment Market in 2035?

The Therapeutics segment is expected to be valued at 0.5 USD Billion in 2035.

Which key players are leading the Global Monkeypox Vaccine and Treatment Market?

Major players in the market include Siga Technologies, Pfizer, Moderna, Sanofi, and Merck and Co.

What is the expected market value for the Diagnostics segment by 2035?

The Diagnostics segment of the market is anticipated to reach a value of 0.35 USD Billion by 2035.

How will the market size of the Asia-Pacific (APAC) region change from 2024 to 2035?

The APAC region is expected to grow from a market value of 0.05 USD Billion in 2024 to 0.2 USD Billion in 2035.

What market value is projected for the Vaccines segment in 2035?

The Vaccines segment is expected to be valued at 0.65 USD Billion in 2035.

What is the expected market value of the South America region for the Global Monkeypox Vaccine and Treatment Market in 2035?

The South America region is projected to reach a market value of 0.1 USD Billion by 2035.

Download Free Sample

Kindly complete the form below to receive a free sample of this Report

No regional reports available for this market.

No country-specific reports available for this market.

Customer Stories
Case Study
Aerospace & Defense
Future of Dismounted Soldier Systems Market Trends & Adoption Roadmap 2019–2035

Compare Licence

×
Features License Type
Single User Multiuser License Enterprise User
Price $4,950 $5,950 $7,250
Maximum User Access Limit 1 User Upto 10 Users Unrestricted Access Throughout the Organization
Free Customization ✓ ✓ ✓
Direct Access to Analyst ✓ ✓ ✓
Deliverable Format ✓ ✓ ✓
Platform Access ✗ ✗ ✓
Discount on Next Purchase 10% 15% 15%
Printable Versions ✗ ✗ ✓